Intralesional collagenase in the treatment of Peyronie's disease - Abstract

The objective of intralesional pharmacotherapy in the treatment of Peyronie's disease is to deliver large doses of pharmacologic agents that can have a local effect on wound remodeling, with minimal side effects.

Guidelines for the treatment of peyronie's disease published in the Journal of Sexual Medicine and the European Association of Urology offer no grade A evidence of efficacy with multiple agents such as steroids, verapamil and interferon. Intralesional collagenase is the first drug to be approved by the United States Food and Drug Administration for the treatment of Peyronie's disease. This is based on grade A evidence. The purpose of this update is to review the literature and current data on intralesional collagenase in the treatment of Peyronie's disease.

Written by:
Honig SC.   Are you the author?
Department of Urology, Yale University, 330 Orchard St, Suite 164, New Haven, CT 06511, USA.

Reference: Ther Adv Urol. 2014 Apr;6(2):47-53.
doi: 10.1177/1756287213509849


PubMed Abstract
PMID: 24688600

UroToday.com Peyronie's Section

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe